The Procter & Gamble Company (BVMF:PGCO34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 1.76T -11.8% |
| Revenue (ttm) | 450.90B +3.3% |
| Net Income | 81.62B +0.5% |
| EPS | 34.32 +1.8% |
| Shares Out | n/a |
| PE Ratio | 21.52 |
| Forward PE | 20.26 |
| Dividend | 1.05 (1.95%) |
| Ex-Dividend Date | Jul 23, 2026 |
| Volume | 1,155 |
| Open | 54.84 |
| Previous Close | 54.29 |
| Day's Range | 53.76 - 54.84 |
| 52-Week Range | 49.68 - 61.75 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About BVMF:PGCO34
The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The company offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; antiperspirants, deodorants, and personal cleansing products under the Native, Old Spice, Safeguard, and Secret brands; and facial moisturizers, cleaners, and treatments under the Olay and SK-II brands. ... [Read more]
Financial Performance
In fiscal year 2026, BVMF:PGCO34's revenue was $87.03 billion, an increase of 3.26% compared to the previous year's $84.28 billion. Earnings were $15.75 billion, an increase of 0.45%.
Financial numbers in USD Financial StatementsNews
Beauty, health and wellness are converging into one retail category
As consumers prioritize holistic retail purchases, beauty, health and wellness are increasingly becoming one category and one consumer budget. The delineation of those categories is becoming less defi...
The Procter & Gamble Company Transcript: Barclays 19th Annual Global Consumer Conference
Leadership highlighted a continued focus on execution and technology to drive growth, with no major changes to the core strategy. Key initiatives include automation, AI-driven R&D, and targeted interventions by market and category, with visible impacts expected within 12–24 months.
P&G to Webcast Fireside Chat From the Barclays Global Consumer Staples Conference, September 10
CINCINNATI--(BUSINESS WIRE)--Andre Schulten, Chief Financial Officer of The Procter & Gamble Company (NYSE:PG) will be a featured speaker at the Barclays Global Consumer Staples Conference on Thursday...
6 Dividend Aristocrats to Play Right Now
Medtronic, McCormick and T. Rowe Price are among the stocks that have outperformed the S&P 500 over the past three months—and have dividend yields of at least 3%.
The Procter & Gamble Company Proxy statement: Proxy filing
The Procter & Gamble Company filed a proxy statement on August 28, 2026, providing details for shareholder voting and corporate governance matters.
The Procter & Gamble Company Proxy statement: Proxy filing
The Procter & Gamble Company filed a proxy statement on August 28, 2026, providing details for shareholder voting and corporate governance matters.
Procter & Gamble downgraded to Hold from Buy at Argus
Argus analyst Chris Graja downgraded Procter & Gamble to Hold from Buy. Procter & Gamble faces near-term pressure from economic and geopolitical uncertainty, rising input costs, and weak consumer sent...
Procter & Gamble downgraded to Hold from Buy at Argus
Argus analyst Chris Graja downgraded Procter & Gamble to Hold from Buy.
Wayfair Sees Recovery in U.S. Furniture Demand; SpaceX Is Eyeing $1 Trillion in Revenue; P&G's $3.8 Billion Bet
Good morning, CFOs. Wayfair CFO Kate Gulliver on signs of a rebound in the U.S.; Elon Musk outlined ambitious targets for SpaceX following its first-ever earnings report; Procter & Gamble will buy sup...
L Catterton announces sale of Thorne to Procter & Gamble for $3.8B
L Catterton announced that it has signed a definitive agreement to sell Thorne, which it calls “a leader in science-backed health and wellness solutions,” to The Procter & Gamble Company…
L Catterton Announces Sale of Thorne to The Procter & Gamble Company for $3.8 Billion
L Catterton's Deep Category Conviction and Brand Vision Allowed for Accelerated Growth and Fortified Thorne's Position as the Premier Trusted Brand in Science-Backed Wellness GREENWICH, Conn., Aug. 4,...
Procter & Gamble (PG) Stock Jumps on News of a Deal to Buy Thorne
Procter & Gamble ($PG) stock was up on Tuesday after the branded consumer products company said it will acquire supplement maker Thorne for $3.8 billion. CEO Shailesh Jejurikar said as much during…
M&A News: Procter & Gamble (PG) to Acquire Supplements Firm Thorne for $3.8 Billion
P&G is looking to grow its healthcare division and reach younger consumers.
Thorne confirms agreement to be acquired by Procter & Gamble
Thorne announced that it has entered into a definitive agreement to be acquired by Procter & Gamble. The transaction is expected to close later this year, subject to customary closing…
Thorne Enters into Definitive Agreement to Be Acquired by Procter & Gamble
Acquisition positions Thorne to continue advancing its mission while building on its legacy of science, quality, innovation, and trust SUMMERVILLE, S.C., Aug. 4, 2026 /PRNewswire/ -- Thorne, the leade...
P&G Agrees to Buy Supplements Maker for $3.8 Billion
The consumer-goods giant will buy Thorne to bolster its presence in the beauty and wellness industry.
P&G is acquiring supplements maker Thorne, CEO Jejurikar tells CNBC
Tide maker Procter & Gamble will announce the acquisition of supplements maker Thorne on Tuesday, P&G CEO Shailesh Jejurikar told CNBC in an interview.
Procter & Gamble CEO says will be announcing acquisition of Thorne today
Shailesh Jejurikar, President and CEO of Procter & Gamble, made the comment while being interviewed on CNBC. Jejurikar confirms that P&G is buying Thorne for $3.8B.
Procter & Gamble will acquire supplements brand Thorne, CEO tells CNBC
Procter & Gamble is buying supplement brand Thorne. P&G CEO Shailesh Jejurikar said the acquisition is play to grow the company's health business on CNBC's "Squawk on the Street.
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
Procter & Gamble price target lowered to $162 from $163 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Procter & Gamble to $162 from $163 and keeps a Buy rating on the shares.
Procter & Gamble price target lowered to $160 from $166 at BofA
BofA lowered the firm’s price target on Procter & Gamble to $160 from $166 and keeps a Buy rating on the shares. The firm raised its FY27 and FY28 adjusted…
Procter & Gamble price target lowered to $170 from $181 at Citi
Citi lowered the firm’s price target on Procter & Gamble to $170 from $181 and keeps a Buy rating on the shares. The company reported “soft” fiscal Q4 results but…
HSBC downgrades Procter & Gamble to Hold after ‘weak’ Q4
HSBC analyst Diego Serrano downgraded Procter & Gamble to Hold from Buy with a price target of $149, down from $182. The company reported “weak” fiscal Q4 results and its…
Procter & Gamble downgraded to Hold from Buy at HSBC
HSBC downgraded Procter & Gamble to Hold from Buy with a $142 price target